| In the USA, one in eight women develop invasive breast cancer at some point of her life, and 70% of the cancers are estrogen receptor positive and thus are treated with antiestrogen therapy. However, half of the treated patients exhibit resistance to tamoxifen, including de novo resistance and recurrence. By using a novel preclinical rat model, I studied the effect of timing of dietary components (genistein and obesity- inducing high fat) on mammary tumor responsiveness to tamoxifen therapy and the risk of recurrence. (Abstract shortened by ProQuest.). |
